侯金林教授课题组SCI论文发表
2017/11/22浏览量：1893编辑：管理员来源：实验室
1.Fan R, Yin X, Liu Z, Liu Z, Lau G, Hou J. A hepatitis B-free generation in China: from dream to reality. Lancet Infect Dis. 2016 Oct;16(10):1103-5. doi: 10.1016/S1473-3099(16)30327-9. (JCR1，IF 19.864 )
2.Fan R, Sun J, Hou J. The combination therapy with tenofovir and peginterferon may not be translated into current clinical practice. Gastroenterology. 2016 May;150(5):1253-1254. doi: 10.1053/j.gastro.2015.12.046. (JCR1，IF 18.392 )
3.Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J; Chronic Hepatitis B Study Consortium. Baseline Quantitative Hepatitis B Core Antibody Titer Alone Strongly Predicts HBeAg Seroconversion across Chronic Hepatitis B Patients Treated with Peg-Interferon or Nucleos(t)ide Analogues. Gut. 2016 Feb;65(2):313-20. doi: 10.1136/gutjnl-2014-308546. (JCR1，IF 16.658)
4.Sun J, Ma H, Xie Q, Xie Y, Sun Y, Wang H, Shi G, Wan M, Niu J, Ning Q, Yu Y, Zhou H, Cheng J, Kang W, Xie Y, Fan R, Wei L, Zhuang H, Jia J, Hou J. Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. J Hepatol. 2016 Oct;65(4):674-82. doi: 10.1016/j.jhep.2016.05.024.. (JCR1，IF 12.486)
5.Qi X, Liu F, Li Z, Chen S, Liu Y, Yang Y, Hou J. Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis. J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277-8. doi: 10.1016/j.jhep.2017.07.037. (JCR1，IF 12.486)
6.Fan R, Yin X, Hou J*.Prevention of Peripartum Hepatitis B Transmission. New Engl J Med. 2016 Oct 13;375(15):1496. (JCR1，IF 72.406)
7.Xu Y, Liu Y, Zhao M, Chen Y, Xie C, Gong M, Deng H, Li X, Sun J, Hou J, Wu H, Wang Z. Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy. Front Immunol. 2017 Sep 14;8:1142. doi: 10.3389/fimmu.2017.01142. (JCR2，IF 6.429)
8.Liu C, Huang X, Werner M, Broering R, Ge J, Li Y, Liao B, Sun J, Peng J, Lu M, Hou J, Zhang X. Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy. Front Immunol. 2017 Mar 23;8:323. doi: 10.3389/fimmu.2017.00323 (JCR2，IF 6.429)
9.Pang J, Zhang G, Lin Y, Xie Z, Liu H, Tang L, Lu M, Yan R, Guo H, Sun J, Hou J, Zhang X. Transforming growth factor β-activated kinase 1 transcriptionally suppresses hepatitis B virus replication. Sci Rep. 2017 Jan 3;7:39901. doi: 10.1038/srep39901. (JCR3，IF 4.259)
10.Liang X, Xie Q, Tan D, Ning Q, Niu J, Bai X, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Chen Y, Rong F, Sun J, Jia J, Hou J. Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study. J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12814. (JCR2，IF 4.122)
11.Ning L, Lin W, Hu X, Fan R, Liang X, Wu Y, Shen S, Yu R, Sun J, Hou J. Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey. J Viral Hepat. 2017 Nov;24(11):1043-1051. doi: 10.1111/jvh.12733. (JCR2，IF 4.122)
12.Han Y, Wu Y, Yang C, Huang J, Guo Y, Liu L, Chen P, Wu D, Liu J, Li J, Zhou X , Hou J. Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy. J Transl Med. 2017 Mar 22;15(1):64. doi: 10.1186/s12967-017-1165-0. (JCR2，IF 3.786)
13.Tang L, Zhong R, He X, Wang W, Liu J, Zhu Y, Li Y, Hou J. Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis. J Gastroenterol Hepatol. 2017 Mar;32(3):659-666. doi: 10.1111/jgh.13534. (JCR3，IF 3.452)
14.Deng G, Ge J, Liu C, Pang J, Huang Z, Peng J, Sun J, Hou J, Zhang X. Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy. Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):386-398. doi: 10.1016/j.clinre.2016.12.006. (JCR4，IF 2.323)
15.Li Y, Wang W, Tang L, He X, Yan X, Zhang X, Zhu Y, Sun J, Shi Y, Ma X, Mackay IR, Gershwin ME*, Han Y*, Hou J*. Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis. Hepatology. 2015: Jun. (JCR1,IF 11.711 )
16.Zhou B, Dong H, He Y, Sun J, Jin W, Xie Q, Fan R, Wang M, Li R, Chen Y, Xie S, Shen Y, Huang X, Wang S, Lu F, Jia J, Zhuang H, Locarnini S, Zhao GP*, Jin L*, Hou J*. Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. Sci Rep. 2015: Nov 24. (JCR2,IF 5.228 )
17.Li Y, Tang L, Hou J*. Role of interleukin-21 in HBV infection: friend or foe? Cell Mol Immunol. 2015: May. (JCR3,IF 5.193)
18.Huang Z, Ge J, Pang J, Liu H, Chen J, Liao B, Huang X, Zuo D, Sun J, Lu M, Zhang X*, Hou J*. Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy. Antiviral Res. 2015:Jun. (JCR2,IF 4.909)
19.Hou JL*, Gao ZL, Xie Q, Zhang JM, Sheng JF, Cheng J, Chen CW, Mao Q, Zhao W, Ren H, Tan DM, Niu JQ, Chen SJ, Pan C, Tang H, Wang H, Mao YM, Jia JD, Ning Q, Xu M, Wu SM, Li J, Zhang XX, Ji Y, Dong J, Li J. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks. J Viral Hepat. 2015: Feb. (JCR2,IF 4.179 )
20.Yu R#, Sun J#, Zheng Z, Chen J, Fan R, Liang X, Zhu Y, Liu Y, Shen S, Hou J*. Association between Vitamin D level and viral load or fibrosis stage in chronic hepatitis B patients from Southern China. J Gastroenterol Hepatol. 2015: Mar. (JCR3,IF 3.322 )
21.Liang X, Cheng J, Sun Y, Chen X, Li T, Wang H, Jiang J, Chen X, Long H, Tang H, Yu Y, Sheng J, Chen S, Niu J, Ren H, Shi J, Dou X, Wan M, Jiang J, Xie Q, Shi G, Ning Q, Chen C, Tan D, Ma H, Sun J, Jia J, Zhuang H, Hou J*. Randomized, Three-arm Study to Optimize Lamivudine Efficacy in HBeAg Positive Chronic Hepatitis B Patients. J Gastroenterol Hepatol. 2015: Apr. (JCR3,IF 3.322 )
22.Hou JL*, Xu D, Shi G, Wan M, Goodman Z, Tan D, Xie Q, Chen C, Wei L, Niu J, Wang Q, Ren H, Wang Y, Jia J, Bao W, Dong Y, Trylesinski A, Naoumov NV. Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. Adv ther. 2015: Aug. (JCR3,IF 2.503)
23.Wang Y*, Hou JL. Current strategies for quantitating fibrosis in liver biopsy. Chin Med J (Engl). 2015: Jan 20. (JCR4,IF 0.957)
24.Xu S, Wang Y, Tai DC, Wang S, Cheng CL, Peng Q, Yan J, Chen Y, Sun J, Liang X, Zhu Y, Rajapakse JC, Welsch RE, So PT, Wee A, Hou J*, Yu H*.qFibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients.J Hepatol. 2014 Aug;61(2):260-9. 49.( JCR1, IF=10.401)
25.Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J*.The 104-week efficacy and safety of telbivudine based optimization strategy in chronichepatitis B patients: A randomized, controlled study.Hepatology. 2014 Apr;59(4):1283-92.38.( JCR1, IF=11.19)
26.Lai Q, Ma S, Ge J, Huang Z, Huang X, Jiang X, Li Y, Zhang M, Zhang X, Sun J, Abbott WG, Hou J*.TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B. PLOS One.2014 Feb 14;9(2):e88475. 51. (JCR3, IF=3.534)
27.Yu R, Fan R, Hou J. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China.Front Med. 2014 Jun;8(2):135-44.. Epub 2014 May 8. Review. (JCR4, IF=1.8)
